Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain zapping study seeks to rewire social circuits in autism

NCT ID NCT06214065

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a non-invasive brain stimulation technique called TMS can change brain activity related to understanding others' thoughts (mentalizing) in young adults with autism. Researchers will compare brain scans before and after stimulation in 80 participants, including some without autism. The goal is to learn how the brain's social network responds to stimulation, not to treat symptoms directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Estimated full-scale IQ\>80 * Right handed * Fluent in English * Individual can cooperate with all study's procedures * No history of neurological disorder (e.g. epilepsy) or neurosurgery * No major medical condition (e.g. cancer, heart failure) * No history of significant head injury * No primary relatives with history of any neurological disorder with a potentially hereditary basis, including epilepsy or MS * No current use of medications with psychotropic (e.g., benzodiazepines) or anti- or pro-convulsants * No current substance use (determined by urine screen and breathalyzer in all visits) * Negative urine pregnancy (women) test at time of MRI scans * No MR contra-indications (e.g. in-body metal implant, severe claustrophobia) * No previous participation in our lab in a study including the Domino fMRI task * For ASD: Stable medication treatment 4 weeks prior to study enrollment * For Control Group: No current or history of psychiatric disorders, other than simple phobia, and/or primary relatives with ASD Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autism spectrum disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Olin Neuropsychiatry Research Center (ONRC)

    RECRUITING

    Hartford, Connecticut, 06106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.